Several research teams are investigating new genome sequencing research headquartered in Vancouver to supercharge the discovery of tailored treatments.
The Vancouver Prostate Centre is currently spearheading a clinical trial that aims to develop more precise treatments for prostate cancer patients. The study, called the Genomic-biomarker-selected Umbrella Neoadjuvant Study (GUNS), will be conducted across multiple sites and will utilize genomic markers to determine the most effective treatment options for participants. Dr. Lucia Nappi and Dr. Martin Gleave, both researchers at the Vancouver Coastal Health Research Institute (VCHRI), will be leading the trial.
Click here to read more.